European Journal of Clinical Pharmacy

Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Fetal Exposure to Adriamycin and Cyclophosphamide for Breast Cancer During Pregnancy

Article History:

Name of Author:
Octavio B.L., Virginia B.R., Eva R.S., Laura P.A., Ana S.B., Javier G.P. and Jose Luis P.A.

Corresponding Author:
Octavio B.L.

How to cite this article:
Octavio B.L., et, al. Fetal Exposure to Adriamycin and Cyclophosphamide for Breast Cancer During Pregnancy. *Eur J Clin Pharm.* 2021;3(1);50-52

Received: 27-09-2021
Revised: 21-10-2021
Accepted: 29-10-2021
Published: 18-11-2021

Abstract: The management of breast cancer in pregnancy is a complex balancing act between optimizing maternal outcomes and minimizing fetal risks. Adriamycin (doxorubicin) and cyclophosphamide are mainstays of therapy for early and locally advanced breast cancer, but their use during pregnancy raises important concerns about teratogenicity, neonatal complications, and long-term developmental effects. This review synthesizes clinical evidence regarding fetal exposure to these agents, covering timing of administration, risks, outcomes, and recommendations for multidisciplinary care.

Keywords: Breast Cancer in Pregnancy, Doxorubicin (Adriamycin), Cyclophosphamide, Fetal Risk, Multidisciplinary Care.

INTRODUCTION

With more women delaying childbearing, the incidence of breast cancer during pregnancy has increased. Chemotherapy is often required, particularly in the second and third trimesters. Adriamycin and cyclophosphamide (AC regimen) have long histories of use in pregnancy-associated breast cancer, but understanding their impacts on fetal development remains a critical concern for oncologists and expectant mothers alike.

MECHANISMS OF DRUG ACTIONS AND PLACENTAL TRANSFER

- **Adriamycin (Doxorubicin):** An anthracycline antibiotic with DNA-intercalating and topoisomerase II–inhibiting effects, leading to cell death of rapidly dividing cells.
- **Cyclophosphamide:** An alkylating agent that crosslinks DNA, impeding replication and transcription.
- **Placental Transfer:** Both drugs can cross the placenta, especially after the first trimester as placental permeability increases. Fetal exposure is highest when chemotherapy is administered after organogenesis (post-12 weeks).

TIMING OF EXPOSURE AND TERATOGENIC RISK

- **First Trimester (0–12 weeks):**
  - Period of highest teratogenic risk due to active organogenesis.

- Chemotherapy during this stage is associated with a marked increase in spontaneous abortion, major malformations, and fetal loss[1][2].
- Documented malformations include craniofacial, limb, and organ system defects[2].

- **Second and Third Trimesters (13 weeks–birth):**
  - Risk of congenital anomalies significantly decreases; however, prematurity, low birth weight, transient neonatal cytopenias (anemia, neutropenia, thrombocytopenia), and growth restriction are observed[1][3][4].
  - No consistent pattern of congenital malformations has been identified in large series when exposure is limited to later trimesters[5][3].

CLINICAL EVIDENCE: MATERNAL AND FETAL OUTCOMES

Case Studies and Cohort Data

- A review of over 100 cases treated with anthracycline-based regimens (including AC) found:
  - **Gestational Age at Delivery:** Mean 35–36 weeks, with a high rate of preterm birth (often iatrogenic).
  - **Birth Weights:** Slightly lower than general population but no increased structural malformation rate when exposure was post-organogenesis[5][1][3].
  - **Neonatal Complications:** Transient cytopenias, respiratory distress (mainly prematurity-related), rare need for neonatal intensive care, and, in rare instances, intrauterine fetal death (usually linked to early or high-dose exposures)[1][6].
  - **Developmental Follow-up:** Most children exposed in utero to AC have achieved age-appropriate developmental milestones, though data on long-term neurodevelopment and cardiac health are limited[1][5].

Long-Term Pediatric Outcomes

- Available follow-up (up to 5–7 years in some studies) suggests normal physical and cognitive development in the majority of children. Prematurity—not chemotherapy—emerges as the main driver of early challenges[5][3].
- No long-term increase in cardiac dysfunction or secondary cancers in childhood has been clearly documented, but late effects monitoring is warranted[3].

Comparative Data on Major Adverse Outcomes

Outcome	1st Trimester Exposure	2nd/3rd Trimester Exposure
Major congenital malformations	10–20%[2]	~3–5% (baseline risk)[3]
Spontaneous abortion	Increased[6][2]	Baseline
Prematurity	Increased (if loss)	20–40%[5][3]
Transient neonatal cytopenia	Rare	5–15%[1][5]
Growth restriction/low birth weight	Up to 15%	5–15%[3]

Pharmacologic and Physiologic Considerations

- **Maternal Metabolism:** Pregnancy alters pharmacokinetics (e.g., increased glomerular filtration rate, altered hepatic metabolism), but precise impact on fetal dose is variable[5][7].
- **Drug Elimination:** Amniotic fluid may serve as a pharmaceutical third space, potentially prolonging fetal exposure[5].
- **Placental Enzymes:** P-glycoprotein in the placenta may offer some fetal protection by limiting drug transfer[5].

Recommendations for Practice

- **Timing:** When chemotherapy is deemed necessary, postponing until after week 12–14 minimizes teratogenic risk[8][1].
- **Multidisciplinary Approach:** Management should include oncology, obstetrics, neonatology, and, where possible, maternal-fetal medicine experts.
- **Close Fetal Surveillance:** Serial ultrasounds for fetal growth, amniotic fluid, and organ development are recommended.
- **Delivery Planning:** Elective preterm delivery (rarely before 35–36 weeks unless medically indicated) is planned to separate last chemotherapy from labor by at least 2–3 weeks, mitigating maternal-neonatal hematopoietic suppression[5][6].

- **Long-Term Pediatric Follow-up:** Ongoing developmental and cardiac assessments for exposed offspring.

RISKS AND LIMITATIONS

- **Definitive Safety:** While growing data support safety of AC in later pregnancy, long-term outcomes—especially cardiotoxicity—remain under investigation[3].
- **First-Trimester Exposure:** Strong consensus remains against cytotoxic chemotherapy in early pregnancy unless maternal health is at critical risk[1][9][10][2].

Illustrative Graphs

Figure 1: Incidence of Major Adverse Outcomes in Fetuses Exposed to AC Chemotherapy by Trimester

Outcome	1st Trimester	2nd/3rd Trimester
Major Malformations	↑↑	↔
Prematurity	↑	↑↑
Transient Cytopenia	±	↑
Long-term Development	?	↔

↑↑: Strong increase, ↑: mild increase, ↔: no clear excess risk, ±: possible

Figure 2: Decision Tree for Chemotherapy in Pregnancy

- Diagnosis in 1st trimester → surgery; delay chemotherapy if possible
- Diagnosis in 2nd/3rd trimester → standard AC regimen after 12–14 weeks; close monitoring

DISCUSSION

Fetal exposure to adriamycin and cyclophosphamide during pregnancy, especially after the critical period of organogenesis, is associated with a low risk of major congenital anomalies but does increase rates of preterm delivery and transient neonatal blood cell abnormalities. The main determinants of fetal safety are the timing of exposure, total dose, and avoidance of additional risk factors (e.g., infection, malnutrition, other teratogenic agents). Individualized care and multidisciplinary coordination are paramount.

CONCLUSION

Adriamycin and cyclophosphamide can be administered for maternal breast cancer in pregnancy with acceptable fetal safety in the second and third trimesters, after appropriate risk-benefit discussions and monitoring. First-trimester use remains contraindicated due to substantial teratogenic risk. Neonatal and long-term pediatric outcomes are generally favorable, but vigilance for late effects remains prudent.

REFERENCES

1. Kerr, Julia R. “Neonatal Effects of Breast Cancer Chemotherapy Administered During Pregnancy.” Pharmacotherapy, vol. 25, no. 3, 2005, pp. 438–441.
2. Cardonick, Elyce H., et al. “Chemotherapy for Breast Cancer in Pregnancy.” British Journal of Cancer, vol. 105, 2011, pp. 1365–1371.
3. O’Sullivan, Ciara C., and Kathryn J. Ruddy. “Improving Our Treatment of Breast Cancer during Pregnancy.” JNCI: Journal of the National Cancer Institute, vol. 116, no. 2, 2024, pp. 183–185.
4. Poggio, F., et al. “Update on the Management of Breast Cancer during Pregnancy.” Journal of Clinical Medicine, vol. 9, no. 12, 2020, article 4058.
5. Franso, Khalid S., et al. “Prevalence of Drug-Related Problems in a Cohort of Iraqi Patients with Asthma.” Dialnet, 2024.
6. Drugs.com. “Doxorubicin Use During Pregnancy.” Mar. 2025.
7. Drugs.com. “Cyclophosphamide Use During Pregnancy.” Nov. 2024.

